AUS
NZ
UK
CA
USA
IND
Highlights
- Opthea receives significant R&D tax incentive from the Australian Taxation Office.
- Funding supports sozinibercept development for wet age-related macular degeneration (AMD).
- Phase 3 trials underway, aiming to improve outcomes for severe vision impairment.
Melbourne-based Opthea, a biopharmaceutical company listed on the ASX as (ASX:OPT), recently secured a significant boost in its research and development efforts with a $15.9 million R&D tax incentive granted by the Australian Taxation Office. This funding aims to advance the development of sozinibercept, Opthea’s lead candidate therapy for treating wet age-related macular degeneration (AMD), a prevalent and serious eye condition.
Wet AMD is a progressive disease that affects central vision due to abnormal blood vessel growth under the retina, which can lead to leakage and damage over time. This form of vision impairment is particularly challenging, as it impacts activities such as reading and recognizing faces. Currently, treatments focus on using anti-VEGF-A drugs to inhibit the growth factor that stimulates blood vessel growth, but these methods provide only partial control of the disease.
Opthea’s Next-Generation Treatment
Opthea’s sozinibercept is an advanced therapeutic option designed to improve upon existing treatments by targeting additional growth factors, VEGF-C and VEGF-D. As a soluble protein trap, sozinibercept works alongside standard anti-VEGF-A inhibitors to manage a broader range of disease-causing factors, including inflammation, vessel leakage, and abnormal growth. This dual-action approach aims to provide better overall control of wet AMD symptoms, potentially delivering improved vision outcomes.
The development of sozinibercept is progressing through two pivotal Phase 3 clinical trials named COAST and ShORe, which will evaluate the drug’s efficacy in larger patient populations. Data from these trials is expected in early to mid-2025, providing critical insights into the therapy's effectiveness and its potential to address limitations in existing anti-VEGF therapies.
Financial Strengthens Clinical Progress
Opthea’s recent funding injection through the R&D tax incentive strengthens its financial foundation, allowing for further clinical advancements in the Phase 3 trials. According to Frederic Guerard, CEO of Opthea, this substantial financial support positions the company to pursue its goal of achieving more effective vision improvements for patients with wet AMD. Guerard expressed optimism that the dual-action approach of sozinibercept will help address critical needs in the management of wet AMD, offering new hope for patients with limited treatment options.
While shares of Opthea currently show a dip, with a 6.43% drop to 65.5 cents, the substantial R&D funding and upcoming trial results underscore the company’s commitment to pioneering treatments for severe vision impairment, aiming to reshape outcomes for AMD patients worldwide.
